Login

Consolidated Balance Sheets

In millions of USD, except per-share amounts
Q1 FY2023
As of Mar 31, 2023
Q4 FY2022
As of Dec 31, 2022
Q3 FY2022
As of Sep 30, 2022
Q2 FY2022
As of Jun 30, 2022
Q1 FY2022
As of Mar 31, 2022
Q4 FY2021
As of Dec 31, 2021
Q3 FY2021
As of Sep 30, 2021
Q2 FY2021
As of Jun 30, 2021
Q1 FY2021
As of Mar 31, 2021
Q4 FY2020
As of Dec 31, 2020
Q3 FY2020
As of Sep 30, 2020
Current Assets
Cash
Prepaid expenses and other current assets
Total Current Assets
Cash held in Trust Account
TOTAL ASSETS
Current Liability – Accounts payable and accrued expenses
Derivative warrant liabilities
Deferred underwriting fee payable
Current Liabilities
Promissory note – related party
Accounts payable and accrued expenses
Promissory notes – related party
Promissory notes - working capital
Class A ordinary shares tendered for redemption (Note 6)
Due to affiliate
Total Current Liabilities
Derivative warrant liabilities
Deferred underwriting fee payable
Total Liabilities
Class A ordinary shares subject to possible redemption, 517,354 at $10.53 per share as of March 31, 2023, and $10.43 per share as December 31, 2022, respectively
Shareholders’ Deficit
Class A ordinary shares, $0.0001 par value; 200,000,000 shares authorized at March 31, 2023 and December 31, 2022
Class A Ordinary Shares
Class B Ordinary Shares
Class B ordinary shares, $0.0001 par value; 20,000,000 shares authorized; 3,593,750 shares issued and outstanding at March 31, 2023 and December 31, 2022
Additional paid-in capital
Accumulated deficit
Class A Ordinary Shares
Class B Ordinary Shares
Total Shareholders’ Deficit
TOTAL LIABILITIES AND SHAREHOLDERS’ DEFICIT

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support